OCA
SURF

Octagon Capital Advisors’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Octagon Capital Advisors’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,300,000
Closed -$6.76M – 25
2022
Q1 		$6.76M Buy
+2,300,000
New +$8.06M 1.46% 17

Other funds holding SURF

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Octagon Capital Advisors's SURF Position: Q2 2022 in Review

Octagon Capital Advisors sold out of Surface Oncology, Inc. Common Stock (SURF) in Q2 2022, closing a stake of 2,300,000 shares — an estimated $6.76M sold.

Octagon Capital Advisors first reported a position in SURF in Q1 2022 and held it in 1 quarter. The position peaked at $6.76M in Q1 2022. 84 funds tracked by Wall St. Rank hold SURF as of Q2 2022.

  • Octagon Capital Advisors reported no remaining Surface Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 2,300,000 Surface Oncology, Inc. Common Stock shares in Q2 2022, an estimated $6.76M.
  • Octagon Capital Advisors first reported a position in Surface Oncology, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Octagon Capital Advisors's Surface Oncology, Inc. Common Stock position peaked at $6.76M in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q2 2022.

Based on Octagon Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.